Individual Analysis of Mice Vaccinated against a Weakly Immunogenic Self Tumor-Specific Antigen Reveals a Correlation between CD8 T Cell Response and Antitumor Efficacy
- 15 November 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 171 (10) , 5172-5179
- https://doi.org/10.4049/jimmunol.171.10.5172
Abstract
The weakly immunogenic murine P1A Ag is a useful experimental model for the development of new vaccination strategies that could potentially be used against human tumors. An i.m. DNA-based immunization procedure, consisting of three inoculations with the P1A-coding pBKCMV-P1A plasmid at 10-day intervals, resulted in CTL generation in all treated BALB/c mice. Surprisingly, gene gun skin bombardment with the pBKCMV-P1A vector did not induce CTL, nor was it protective against a lethal challenge with the syngeneic P1A-positive J558 tumor cell line. To speed up the immunization procedure, we pretreated the tibialis anterior muscles with cardiotoxin, which induces degeneration of myocytes while sparing immature satellite cells. The high muscle-regenerative activity observable after cardiotoxin inoculation was associated with infiltration of inflammatory cells and expression of proinflammatory cytokines. A single pBKCMV-P1A plasmid inoculation in cardiotoxin-treated BALB/c mice allowed for sustained expansion of P1A-specific CTL and the induction of strong lytic activity in <2 wk. Cardiotoxin adjuvanticity could not be replaced by another muscle-degenerating substance, such as bupivacaine, or by MF59, a Th1 response-promoting adjuvant. Although this vaccination schedule failed to induce tumor rejection in all immunized mice, the analysis of CD8 T cell responses at an individual mouse level disclosed that the cytotoxic activity of P1A-specific CTL was correlated to the antitumor efficacy. These results highlight the critical need to identify reliable, specific immunological parameters that may predict success or failure of an immune response against cancer.Keywords
This publication has 31 references indexed in Scilit:
- Thrombolytic Treatment of Acute Ischemic StrokeMayo Clinic Proceedings, 2002
- Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological TherapyJournal of Immunotherapy, 2002
- From cancer genomics to cancer immunotherapy: toward second-generation tumor antigensTrends in Immunology, 2001
- DNA Vaccines: Immunology, Application, and OptimizationAnnual Review of Immunology, 2000
- DNA-Based Vaccination against Tumors Expressing the P1A AntigenMethods, 1999
- Induction of tumor antigen-specific immunity using plasmid DNA immunization in miceCancer Gene Therapy, 1999
- Cytokines, tumour-cell death and immunogenicity: a question of choiceImmunology Today, 1997
- DNA-Mediated Immunization in Mice Induces a Potent MHC Class I-Restricted Cytotoxic T Lymphocyte Response to the Hepatitis B Envelope ProteinHuman Gene Therapy, 1995
- Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815European Journal of Immunology, 1995
- The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.The Journal of Experimental Medicine, 1991